Curesponse
Personalized Medicine for Accurate Cancer Treatment
Company Overview
Snapshot
Founded in November 2017 by Guy Neev and Seth Salpeter, Curesponse operates with 11–50 employees. The company has secured $14 million in total capital across two funding rounds from three investors. In February 2023, Curesponse announced that Clalit Health Services, Israel's largest HMO, would provide commercial coverage for its cResponse test.
Business overview
Curesponse is a Health Tech & Life Sciences company focused on personalized cancer medicine. The company has developed cResponse, a combined genomic-functional assay that predicts how cancer treatments will affect a patient’s tumor cells in their native environment. This technology advances prediction capabilities beyond genomics by functionally testing a short list of drugs and drug combinations on the patient’s tumor, preserving its original composition and 3D structure. Curesponse serves the oncology and pharmaceutical sectors, aiming to improve the accuracy of treatment recommendations for cancer patients.
Strategic signal
In May 2023, Curesponse presented positive preliminary clinical results from a multi-center UK study at the AACR Meeting in Orlando, Florida. This signals significant progress in validating their cResponse platform, demonstrating its potential to provide accurate, personalized treatment insights for cancer patients and reinforcing the company's position in the precision oncology market.
Log in to access full profile ›Company Intelligence Q&A
- What is Curesponse's primary technology?
- Curesponse's core technology is the cResponse test, a combined genomic-functional assay designed to predict the effectiveness of cancer treatments by functionally testing drugs on a patient's tumor while preserving its native composition and 3D structure.
- When was Curesponse founded and by whom?
- Curesponse was founded in November 2017 by Guy Neev and Seth Salpeter.
- What was a significant commercial milestone for Curesponse in early 2023?
- In February 2023, Curesponse announced that Clalit Health Services, the largest Israeli HMO, would provide commercial coverage for the cResponse test.
- What clinical progress did Curesponse announce in May 2023?
- In May 2023, Curesponse presented positive preliminary clinical results from a multi-center UK study at the AACR Meeting in Orlando, Florida, demonstrating the efficacy of its precision oncology platform.
- Which investors participated in Curesponse's June 2020 funding round?
- In June 2020, Curesponse secured funding from aMoon Fund and NCL Technology Ventures.